文献速递心力衰竭与心肌病

糖尿病心肌病患者中醛糖还原酶抑制剂AT-001的种族结局:ARISE-HF试验

Racial outcomes in patients with diabetic cardiomyopathy treated with an aldose reductase inhibitor: the ARISE-HF trial
RSS 订阅 · Open Heart

ARISE-HF试验纳入625例糖尿病心肌病患者,随机接受AT-001或安慰剂治疗并随访15个月,主要终点为峰值摄氧量变化。安慰剂组中黑人和西班牙裔患者峰值摄氧量下降幅度大于白人患者(p=0.005)。AT-001在减缓黑人和西班牙裔患者峰值摄氧量下降方面未见统计学显著差异(p=0.29)。

要点

  • 糖尿病心肌病患者中,黑人和西班牙裔较白人疾病进展更快。
  • 安慰剂组黑人患者多数KCCQ评分下降幅度最大。
  • AT-001对峰值摄氧量变化的影响在不同种族间无统计学差异。

核心结论

  • 黑人和西班牙裔糖尿病心肌病患者疾病进展更快,黑人患者功能和生命质量下降最明显。
  • AT-001对峰值摄氧量变化的影响无统计学显著性,不同种族和民族组间效应相似。

研究设计与样本

  • 随机对照试验,625例糖尿病心肌病患者随机接受安慰剂或AT-001治疗,随访15个月。
  • 试验注册号为NCT04083339。

主要发现

  • 安慰剂组黑人患者峰值摄氧量下降–0.74 mL/kg/min,西班牙裔患者下降–1.67 mL/kg/min,白人患者下降–0.23 mL/kg/min(p=0.005)。
  • AT-001组黑人和西班牙裔患者峰值摄氧量分别下降–0.31和–0.62 mL/kg/min,与安慰剂组比较p=0.29。
  • 安慰剂组黑人患者在大多数KCCQ评分中出现最大幅度下降。

关键数值与推荐

  • 主要终点为峰值摄氧量变化,次要终点包括KCCQ评分和老年人身体活动量表评分。
  • 按种族和民族分层分析:黑人、西班牙裔、白人。

临床怎么用

  • 对黑人和西班牙裔糖尿病心肌病患者需更密切监测心功能和生命质量变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background Racial and ethnic differences in diabetic cardiomyopathy (DbCM) exist, with black and Hispanic participants showing poorer health status. It remains unclear whether these differences affect the natural progression of the disease. We aimed to evaluate disease progression in individuals with DbCM, as well as racial differences in the response to AT-001. Methods A total of 625 participants with DbCM were randomised to either placebo or AT-001 and followed for 15 months. The primary outcome was change in peak oxygen uptake (peak VO 2 ) and secondary outcomes included Kansas City Cardiomyopathy Questionnaire (KCCQ) and Physical Activity Scale for the Elderly scores. Analyses were stratified by race and ethnicity (black, Hispanic, white). Results Black and Hispanic participants who received placebo experienced greater declines in peak VO 2 (–0.74 and –1.67 mL/kg/min, respectively) compared with white participants (–0.23 mL/kg/min, p=0.005). AT-001 demonstrated a non-statistically significant trend towards slower declines in peak VO 2 in black and Hispanic participants (–0.31 and –0.62 mL/kg/min, p=0.29, respectively). Black participants who received placebo had the largest declines in most KCCQ scores. Conclusion Black and Hispanic participants with DbCM experienced faster disease progression, with black participants showing the most pronounced functional and quality of life declines. The effect of AT-001 on peak VO 2 changes was not statistically significant with similar effects between racial and ethnic groups (NCT04083339). Trial registration number NCT04083339 .

来源:Open Heart,查看原文。版权归原作者所有。

引用

  1. Open Heart:Racial outcomes in patients with diabetic cardiomyopathy treated with an aldose reductase inhibitor: the ARISE-HF trial

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。